A citation-based method for searching scientific literature

W Balemans, N Patel, M Ebeling, E Van Hul, W Wuyts, C Lacza, M Dioszegi, F G Dikkers, P Hildering, P J Willems, J B G M Verheij, K Lindpaintner, B Vickery, D Foernzler, W Van Hul. J Med Genet 2002
Times Cited: 481







List of co-cited articles
1248 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
W Balemans, M Ebeling, N Patel, E Van Hul, P Olson, M Dioszegi, C Lacza, W Wuyts, J Van Den Ende, P Willems,[...]. Hum Mol Genet 2001
765
54

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
M E Brunkow, J C Gardner, J Van Ness, B W Paeper, B R Kovacevich, S Proll, J E Skonier, L Zhao, P J Sabo, Y Fu,[...]. Am J Hum Genet 2001
662
51

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C Hofbauer, Edith Lau, E Michael Lewiecki, Akimitsu Miyauchi,[...]. N Engl J Med 2016
553
39

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Xiaofeng Li, Yazhou Zhang, Heeseog Kang, Wenzhong Liu, Peng Liu, Jianghong Zhang, Stephen E Harris, Dianqing Wu. J Biol Chem 2005
873
34

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D Meisner, Andreas Grauer. N Engl J Med 2017
403
32

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Y Gong, R B Slee, N Fukai, G Rawadi, S Roman-Roman, A M Reginato, H Wang, T Cundy, F H Glorieux, D Lev,[...]. Cell 2001
31


Romosozumab in postmenopausal women with low bone mineral density.
Michael R McClung, Andreas Grauer, Steven Boonen, Michael A Bolognese, Jacques P Brown, Adolfo Diez-Perez, Bente L Langdahl, Jean-Yves Reginster, Jose R Zanchetta, Scott M Wasserman,[...]. N Engl J Med 2014
640
28

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.
Randall D Little, John P Carulli, Richard G Del Mastro, Josée Dupuis, Mark Osborne, Colleen Folz, Susan P Manning, Pamela M Swain, Shan-Chuan Zhao, Brenda Eustace,[...]. Am J Hum Genet 2002
888
28

High bone density due to a mutation in LDL-receptor-related protein 5.
Lynn M Boyden, Junhao Mao, Joseph Belsky, Lyle Mitzner, Anita Farhi, Mary A Mitnick, Dianqing Wu, Karl Insogna, Richard P Lifton. N Engl J Med 2002
28

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Xiaodong Li, Michael S Ominsky, Qing-Tian Niu, Ning Sun, Betsy Daugherty, Diane D'Agostin, Carole Kurahara, Yongming Gao, Jin Cao, Jianhua Gong,[...]. J Bone Miner Res 2008
626
25

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
Gabriela G Loots, Michaela Kneissel, Hansjoerg Keller, Myma Baptist, Jessie Chang, Nicole M Collette, Dmitriy Ovcharenko, Ingrid Plajzer-Frick, Edward M Rubin. Genome Res 2005
294
25

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Alexander G Robling, Paul J Niziolek, Lee A Baldridge, Keith W Condon, Matthew R Allen, Imranul Alam, Sara M Mantila, Jelica Gluhak-Heinrich, Teresita M Bellido, Stephen E Harris,[...]. J Biol Chem 2008
804
22

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.
Karen Staehling-Hampton, Sean Proll, Bryan W Paeper, Lei Zhao, Patrick Charmley, Analisa Brown, Jessica C Gardner, David Galas, Randall C Schatzman, Peter Beighton,[...]. Am J Med Genet 2002
223
21

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Desmond Padhi, Graham Jang, Brian Stouch, Liang Fang, Edward Posvar. J Bone Miner Res 2011
518
21

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Xiaodong Li, Michael S Ominsky, Kelly S Warmington, Sean Morony, Jianhua Gong, Jin Cao, Yongming Gao, Victoria Shalhoub, Barbara Tipton, Raj Haldankar,[...]. J Bone Miner Res 2009
551
20

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
David G Winkler, May Kung Sutherland, James C Geoghegan, Changpu Yu, Trenton Hayes, John E Skonier, Diana Shpektor, Mechtild Jonas, Brian R Kovacevich, Karen Staehling-Hampton,[...]. EMBO J 2003
696
19

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Kenneth E S Poole, Rutger L van Bezooijen, Nigel Loveridge, Herman Hamersma, Socrates E Papapoulos, Clemens W Löwik, Jonathan Reeve. FASEB J 2005
588
19

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
Olivier Leupin, Elke Piters, Christine Halleux, Shouih Hu, Ina Kramer, Frederic Morvan, Tewis Bouwmeester, Markus Schirle, Manuel Bueno-Lozano, Feliciano J Ramos Fuentes,[...]. J Biol Chem 2011
181
17

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.
Liesbeth Van Wesenbeeck, Erna Cleiren, Jeppe Gram, Rodney K Beals, Olivier Bénichou, Domenico Scopelliti, Lyndon Key, Tara Renton, Cindy Bartels, Yaoqin Gong,[...]. Am J Hum Genet 2003
388
16

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Donald A Glass, Peter Bialek, Jong Deok Ahn, Michael Starbuck, Millan S Patel, Hans Clevers, Mark M Taketo, Fanxin Long, Andrew P McMahon, Richard A Lang,[...]. Dev Cell 2005
16

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.
Karol Estrada, Unnur Styrkarsdottir, Evangelos Evangelou, Yi-Hsiang Hsu, Emma L Duncan, Evangelia E Ntzani, Ling Oei, Omar M E Albagha, Najaf Amin, John P Kemp,[...]. Nat Genet 2012
754
16

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
Mikhail Semënov, Keiko Tamai, Xi He. J Biol Chem 2005
514
15

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.
Monica Florio, Kannan Gunasekaran, Marina Stolina, Xiaodong Li, Ling Liu, Barbara Tipton, Hossein Salimi-Moosavi, Franklin J Asuncion, Chaoyang Li, Banghua Sun,[...]. Nat Commun 2016
127
15

Evidence for osteocyte regulation of bone homeostasis through RANKL expression.
Tomoki Nakashima, Mikihito Hayashi, Takanobu Fukunaga, Kosaku Kurata, Masatsugu Oh-Hora, Jian Q Feng, Lynda F Bonewald, Tatsuhiko Kodama, Anton Wutz, Erwin F Wagner,[...]. Nat Med 2011
942
14

Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures.
Sofia Movérare-Skrtic, Petra Henning, Xianwen Liu, Kenichi Nagano, Hiroaki Saito, Anna E Börjesson, Klara Sjögren, Sara H Windahl, Helen Farman, Bert Kindlund,[...]. Nat Med 2014
180
14

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta.
Christine M Laine, Kyu Sang Joeng, Philippe M Campeau, Riku Kiviranta, Kati Tarkkonen, Monica Grover, James T Lu, Minna Pekkinen, Maija Wessman, Terhi J Heino,[...]. N Engl J Med 2013
219
14

Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Chuwen Lin, Xuan Jiang, Zhongquan Dai, Xizhi Guo, Tujun Weng, Jun Wang, Yinghui Li, Guoyin Feng, Xiang Gao, Lin He. J Bone Miner Res 2009
410
13

Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21.
W Van Hul, W Balemans, E Van Hul, F G Dikkers, H Obee, R J Stokroos, P Hildering, F Vanhoenacker, G Van Camp, P J Willems. Am J Hum Genet 1998
92
14

Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
Antoon H van Lierop, Neveen A T Hamdy, Martje E van Egmond, Egbert Bakker, Freek G Dikkers, Socrates E Papapoulos. J Bone Miner Res 2013
77
16

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, Michael A Bolognese, Jacques P Brown, Nadia S Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S Finkelstein, Harry K Genant,[...]. Lancet 2017
151
13

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
Rutger L van Bezooijen, Bernard A J Roelen, Annemieke Visser, Lianne van der Wee-Pals, Edwin de Wilt, Marcel Karperien, Herman Hamersma, Socrates E Papapoulos, Peter ten Dijke, Clemens W G M Löwik. J Exp Med 2004
551
13

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Scott Taylor, Michael S Ominsky, Rong Hu, Efrain Pacheco, Yudong D He, Danielle L Brown, J Ignacio Aguirre, Thomas J Wronski, Sabina Buntich, Cynthia A Afshari,[...]. Bone 2016
56
23

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Asiri R Wijenayaka, Masakazu Kogawa, Hui Peng Lim, Lynda F Bonewald, David M Findlay, Gerald J Atkins. PLoS One 2011
284
13

Matrix-embedded cells control osteoclast formation.
Jinhu Xiong, Melda Onal, Robert L Jilka, Robert S Weinstein, Stavros C Manolagas, Charles A O'Brien. Nat Med 2011
766
12

A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
Igor Fijalkowski, Ellen Geets, Ellen Steenackers, Viviane Van Hoof, Feliciano J Ramos, Geert Mortier, Ana Maria Fortuna, Wim Van Hul, Eveline Boudin. J Bone Miner Res 2016
33
36

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
Xiaolin Tu, Yumie Rhee, Keith W Condon, Nicoletta Bivi, Matthew R Allen, Denise Dwyer, Marina Stolina, Charles H Turner, Alexander G Robling, Lilian I Plotkin,[...]. Bone 2012
278
12

SOST is a target gene for PTH in bone.
Hansjoerg Keller, Michaela Kneissel. Bone 2005
399
12

WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk.
Hou-Feng Zheng, Jon H Tobias, Emma Duncan, David M Evans, Joel Eriksson, Lavinia Paternoster, Laura M Yerges-Armstrong, Terho Lehtimäki, Ulrica Bergström, Mika Kähönen,[...]. PLoS Genet 2012
166
12

Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone.
Xiaolin Tu, Jesus Delgado-Calle, Keith W Condon, Marta Maycas, Huajia Zhang, Nadia Carlesso, Makoto M Taketo, David B Burr, Lilian I Plotkin, Teresita Bellido. Proc Natl Acad Sci U S A 2015
142
12

The osteocyte: an endocrine cell ... and more.
Sarah L Dallas, Matthew Prideaux, Lynda F Bonewald. Endocr Rev 2013
480
11

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Michael S Ominsky, Fay Vlasseros, Jacquelin Jolette, Susan Y Smith, Brian Stouch, George Doellgast, Jianhua Gong, Yongming Gao, Jin Cao, Kevin Graham,[...]. J Bone Miner Res 2010
295
11

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
R M Neer, C D Arnaud, J R Zanchetta, R Prince, G A Gaich, J Y Reginster, A B Hodsman, E F Eriksen, S Ish-Shalom, H K Genant,[...]. N Engl J Med 2001
11

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Robert R Recker, Charles T Benson, Toshio Matsumoto, Michael A Bolognese, Deborah A Robins, Jahangir Alam, Alan Y Chiang, Leijun Hu, John H Krege, Hideaki Sowa,[...]. J Bone Miner Res 2015
165
11

HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.
Marc N Wein, Jordan Spatz, Shigeki Nishimori, John Doench, David Root, Philip Babij, Kenichi Nagano, Roland Baron, Daniel Brooks, Mary Bouxsein,[...]. J Bone Miner Res 2015
88
11

Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Nicole M Collette, Damian C Genetos, Aris N Economides, LiQin Xie, Mohammad Shahnazari, Wei Yao, Nancy E Lane, Richard M Harland, Gabriela G Loots. Proc Natl Acad Sci U S A 2012
83
12

Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
Ming-Kang Chang, Ina Kramer, Thomas Huber, Bernd Kinzel, Sabine Guth-Gundel, Olivier Leupin, Michaela Kneissel. Proc Natl Acad Sci U S A 2014
63
15

Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.
Corinna Wehmeyer, Svetlana Frank, Denise Beckmann, Martin Böttcher, Christoph Cromme, Ulrich König, Michelle Fennen, Annelena Held, Peter Paruzel, Christine Hartmann,[...]. Sci Transl Med 2016
77
12

Role and mechanism of action of sclerostin in bone.
Jesus Delgado-Calle, Amy Y Sato, Teresita Bellido. Bone 2017
138
10

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris,[...]. JAMA 2016
342
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.